| Röllig, Christoph |
| Completed | 3 | 721 | Europe, RoW | study part 1 - dose daunorubicin, induction cycles | Technische Universität Dresden, University Hospital Dresden, Masaryk University | Leukemia, Myelocytic, Acute | 04/22 | 04/22 | | |
| Recruiting | 2 | 146 | Europe | Venetoclax plus Azacitidine, standard of care chemotherapy plus gemtuzumab ozogamicin | Technische Universität Dresden, University Hospital Heidelberg, AbbVie | Acute Myeloid Leukemia | 09/28 | 09/28 | | |
| Active, not recruiting | 1/2 | 55 | Europe | Venetoclax Oral Tablet, Cytarabin | Technische Universität Dresden, AbbVie | Relapsed Adult AML, Refractory AML | 10/23 | 08/25 | | |
| Recruiting | 1/2 | 214 | Europe | MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO, Rydapt, Mylotarg, MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO, MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO, MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin, MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin | Technische Universität Dresden, Novartis Pharmaceuticals, Pfizer | Acute Myeloid Leukemia | 04/27 | 04/28 | | |
| Recruiting | N/A | 250 | Europe, RoW | | University of Jena | Chronic Myeloid Leukemia in Myeloid Blast Crisis | 06/24 | 06/24 | | |
NCT03188874: Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL) |
|
|
| Recruiting | N/A | 15000 | Europe | | Technische Universität Dresden | Acute Myeloid Leukemia (AML) | 09/30 | 09/30 | | |
